Brief Title
Genetic of Aortic Valve Stenosis - Clinical and Therapeutic Implications
Official Title
Genetic of Aortic Valve Stenosis - Clinical and Therapeutic Implications
Brief Summary
Pathophysiology of Aortic Valve Stenosis remains poorly known. The aim of the present study is to identify genetic factors involved in this disease using a case control trial design.
Detailed Description
Aortic valve stenosis (AS) is the most common valvular disease and the second most common indication for cardiac surgery in Western countries. AS has long been considered as a passive and degenerative process. Recent data challenged this concept, showing that AS is an active and highly regulated process with some similarities to atherosclerosis. However, pathophysiology of AS remains poorly understood and preliminary data suggest that genetic factors may be involved. The aim of the present study is to identify genetic factors involved in this disease using a case control trial design (1000 patients with AS and 1500 controls with no evidence of valve disease). For all patients and controls, blood samples including DNA and echocardiography will be performed.
Study Type
Observational
Primary Outcome
Identification of genetic polymorphisms of fetuin-A, matrix-GLA protein, vitamin D receptor
Secondary Outcome
Identification of other genetic polymorphisms
Condition
Aortic Valve Stenosis
Study Arms / Comparison Groups
aortic stenosis
Description: various age and disease severity
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
2200
Start Date
March 2008
Completion Date
December 2017
Primary Completion Date
December 2017
Eligibility Criteria
Patients: Inclusion criteria : - Age >=18 years - Pure isolated degenerative aortic valve stenosis Exclusion criteria : - Rheumatic, congenital or post-radiation aortic stenosis - Severe renal insufficiency (clearance < 30 ml/min) - Aortic insufficiency > or = grade 2/4 - Other valve disease > or = grade 2/4 Controls Inclusion criteria : - Age >=18 years Exclusion criteria : - Known first degree relative with aortic valve stenosis - Severe renal insufficiency (clearance < 30 ml/min) - Any valve disease > or = grade 2/4
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
David Messika-Zeitoun, MD, ,
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT00647088
Organization ID
P070141
Responsible Party
Sponsor
Study Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
Study Sponsor
David Messika-Zeitoun, MD, Principal Investigator, Assistance Publique - Hôpitaux de Paris
Verification Date
February 2016